[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531596":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":19,"armGroups":11,"interventions":11,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":46,"collaborators":11,"id":48,"slug":11,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":11,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":11,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":11,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Power Life Sciences Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of hidradenitis suppurativa patients who decide to enroll in a clinical research",null,"3 months",{"measure":14,"description":11,"timeFrame":15},"Rate of hidradenitis suppurativa patients who remain in clinical trial to trial completion","12 months",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":17,"timePerspective":18,"maskingInfo":11},"CASE_CROSSOVER","PROSPECTIVE","Patients with hidradenitis suppurativa who are actively considering enrolling in a clinical study for said condition, but have not yet completed enrollment and randomization.",[21],{"name":22,"affiliation":5,"role":23},"Michael B Gill","STUDY_DIRECTOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":28},"CONTACT","415-900-4227","bask@withpower.com",[30],{"facility":31,"status":11,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Power Life Sciences","San Francisco","California","94107","United States","US",{"type":38,"coordinates":39},"Point",[40,41],-122.41942,37.77493,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":45},"https:\u002F\u002Fwww.withpower.com\u002Fcontact-us@withpower.com",{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100531596",false,"NCT06201858","A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa","Examining Engagement Trends Among Participants in Hidradenitis Suppurativa Clinical Trials","Inclusion Criteria:\n\n* Aged ≥ 18 years old\n* Diagnosis of hidradenitis suppurativa\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nExclusion Criteria:\n\n* Female patients who are currently pregnant or nursing\n* Inability to perform regular electronic reporting\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.","ALL","18 Years",{"count":57,"type":58},500,"ESTIMATED","OBSERVATIONAL","This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials. Understanding these factors will significantly improve the relevance and effectiveness of future research endeavors.\n\nUltimately, this trial endeavors to deepen our understanding of the factors impacting hidradenitis suppurativa clinical trial participation. Enhancing participation rates could accelerate the development of innovative treatments for this debilitating condition.",[62],"Hidradenitis Suppurativa",[62],"NOT_YET_RECRUITING","2024-02-09",{"date":67,"type":68},"2024-02-12","ACTUAL",{"date":70,"type":58},"2025-01",{"date":72,"type":58},"2027-01",{"name":5,"class":6},1]